ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,71
0,00%
Dow Jones
40 211,72
0,53%
DAX
18 590,89
-0,95%
Brent Oil
83,695
-0,76%
Bitcoin
63 427,40
-2,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
06/04/201614h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemo...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/04/201614h00GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxa...NASDAQ:PTLAPortola Pharmaceuticals Inc
30/03/201617h50Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
25/03/201621h25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
24/03/201614h44Dow Jones NewsU.S. Hot Stocks: Hot Stocks to WatchNASDAQ:PTLAPortola Pharmaceuticals Inc
24/03/201614h40Dow Jones NewsPortola's Shares Plunge on Blood Clot TrialNASDAQ:PTLAPortola Pharmaceuticals Inc
24/03/201612h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acut...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/03/201609h00GlobeNewswire Inc.Portola Pharmaceuticals to Hold Conference Call on Thursday, March 24, at 8:30 am ETNASDAQ:PTLAPortola Pharmaceuticals Inc
10/03/201601h46GlobeNewswire Inc.Portola Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
10/03/201601h46GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
04/03/201619h15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
29/02/201623h19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/02/201615h37Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:PTLAPortola Pharmaceuticals Inc
19/02/201614h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, Fe...NASDAQ:PTLAPortola Pharmaceuticals Inc
17/02/201623h42GlobeNewswire Inc.Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDANASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201623h35Edgar (US Regulatory)Amended Annual Statement of Changes in Beneficial Ownership (5/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201615h27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
11/02/201620h24Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:PTLAPortola Pharmaceuticals Inc
01/02/201612h55GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 M...NASDAQ:PTLAPortola Pharmaceuticals Inc
26/01/201619h31Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/01/201614h00GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016NASDAQ:PTLAPortola Pharmaceuticals Inc
18/12/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet AlfaNASDAQ:PTLAPortola Pharmaceuticals Inc
09/12/201512h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/12/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematolo...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/12/201514h00GlobeNewswire Inc.Portola Announces Pricing of Public Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
03/12/201522h35GlobeNewswire Inc.Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
12/11/201514h00GlobeNewswire Inc.Portola Pharmaceuticals to Host Analyst and Investor Day on November 19NASDAQ:PTLAPortola Pharmaceuticals Inc
11/11/201516h45GlobeNewswire Inc.The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals’ Phase 3 ANNEXA Studies of Andexanet AlfaNASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201523h11Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201523h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
PX4
SBF 120
EU
CAP
Capgemini
EU
ORA
Orange
EU
RI
Pernod Ricard
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
EU
SGO
Cie de SaintGobain
EU
VK
Vallourec
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés